AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaTechnology, Industry, AgricultureHumanitiesInformation ScienceHealth Care
CarboplatinPaclitaxelAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, PhytogenicDrug Administration ScheduleOvarian NeoplasmsCisplatinAntineoplastic AgentsLung NeoplasmsTreatment OutcomeInfusions, IntravenousCarcinoma, Non-Small-Cell LungDose-Response Relationship, DrugEtoposidePlatinumIfosfamideCombined Modality TherapyArea Under CurveThrombocytopeniaMaximum Tolerated DoseNeutropeniaDisease-Free SurvivalDeoxycytidineTaxoidsToxicity TestsOrganoplatinum CompoundsSurvival AnalysisFallopian Tube NeoplasmsLeukopeniaDoxorubicinDrug Resistance, NeoplasmSurvival RateNeoplasm StagingHematologic DiseasesNeoplasmsTopotecanVinblastineCyclophosphamideBreast NeoplasmsPeritoneal NeoplasmsThiotepaRetinal NeoplasmsAmifostineDrug SynergismCell Line, TumorCarcinoma, Small CellNeoplasm Recurrence, LocalTubulin ModulatorsBridged CompoundsAntibodies, Monoclonal, HumanizedDrug EvaluationDrug HypersensitivityRetinoblastomaEpothilonesNauseaToxicity Tests, AcuteCarcinomaEpirubicinNeoplasms, Glandular and EpithelialFluorouracilFeasibility StudiesSalvage TherapyRemission InductionChemotherapy, AdjuvantPlatinum CompoundsPeripheral Nervous System DiseasesDrug Screening Assays, AntitumorIsocoumarinsAlopeciaTime FactorsGerminomaTesticular NeoplasmsAdenocarcinomaCell SurvivalAdministration, OralVomitingApoptosisSeminomaGranulocyte Colony-Stimulating FactorNeoplasms, Germ Cell and EmbryonalDisease ProgressionTumor Cells, CulturedMice, NudeHead and Neck NeoplasmsEstramustineMesnaTubulinUrologic NeoplasmsGuanineCamptothecinNeoplasms, Unknown PrimaryAntibodies, MonoclonalTaxusP-GlycoproteinXenograft Model Antitumor AssaysDrug InteractionsGenital Neoplasms, FemalePolyethylene GlycolsGlutamatesDrug Delivery Systems
CisplatinGemcitabineArea underWeekly carboplatin and paclitaxelGiven together with paclitaxelNeutropeniaMetastaticEmbryo-fetal toxicityTaxolRegimenHematological toxicityCyclesProgression-Free SurThrombocytopeniaIntravenouslyDisease progressionOvarian cancerChemotherapy in patientsDocetaxel and carboplatinReceive paclitaxelCyclophosphamideRecurrentPulmonary toxicityCombinationNSCLCSurvivalGradeTreatmentBevacizumabTrialEvaluatePharmacokineticsOncologyDosesNeurotoxicityEndometrial cancerPhaseDose levelTolerable
Cisplatin11
Gemcitabine7
  • Methods Patients with platinum-sensitive recurrent ovarian cancer received intravenous (IV) paclitaxel at 60 mg/m 2 followed by IV carboplatin at an area under the curve of 6 and IV pegylated liposomal doxorubicin at 30 mg/m 2 on day 1 in a 28-day cycle (DC-LOP) or IV gemcitabine at 1000 mg/m 2 on days 1 and 8 in a 21-day cycle (GC-LOP). (bmj.com)
  • This randomized phase III trial studies carboplatin, paclitaxel and gemcitabine hydrochloride when given together with or without bevacizumab after surgery to see how well it works in treating patients with ovarian, epithelial, primary peritoneal, or fallopian tube cancer that has come back. (ucsf.edu)
  • Drugs used in chemotherapy, such as carboplatin, paclitaxel and gemcitabine hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (ucsf.edu)
  • A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. (ucsf.edu)
  • They received paclitaxel 175 mg/m 2 , carboplatin area under curve 5, and gemcitabine 800 mg/m 2 on day 1 and gemcitabine 800 mg/m 2 on day 8, every 3 weeks for six courses. (bmj.com)
  • Dose intensity reached 90.8% for carboplatin and paclitaxel and 73.3% for gemcitabine. (bmj.com)
  • Chemotherapy options included nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin. (universimed.com)
Area under1
  • This phase I, open-label, dose-escalation study (ClinicalTrials.gov: NCT00603538) assessed the safety and tolerability of figitumumab (6, 10 and 20 mg/kg) in combination with carboplatin (area under the curve: 6 mg·min/mL) and paclitaxel (200 mg/m(2)) in Japanese patients (N = 19) with chemotherapy-naïve, advanced NSCLC. (omicsdi.org)
Weekly carboplatin and paclitaxel1
Given together with paclitaxel2
  • PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated cancer of unknown primary. (mayo.edu)
  • This phase I/II trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well they work in treating patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. (uchicagomedicine.org)
Neutropenia5
  • However, nine of the first 17 patients developed grade 3 or higher neutropenia, and four developed grade 3 or higher thrombocytopenia while on weekly panitumumab, nab-paclitaxel, and carboplatin. (medpagetoday.com)
  • These data also show that XMT-1536 is well tolerated without the severe toxicities of other ADC platforms such as neutropenia, neuropathy and ocular toxicity. (pipelinereview.com)
  • There was no reported severe neutropenia, peripheral neuropathy or ocular toxicity. (pipelinereview.com)
  • Dose-limiting toxicity (grade 4 neutropenia) occurred in two patients at level 2 (cycle I). Filgrastim was instituted thereafter with cycle I for the next four levels. (psu.edu)
  • Early discontinuation was more common with the dose-dense regimen, and these patients were more likely to experience toxicity, especially neutropenia and anemia. (medscape.com)
Metastatic3
Embryo-fetal toxicity1
Taxol1
  • OBJECTIVE: The purpose of this study was to determine the activity and toxicity of carboplatin and paclitaxel (taxol) in the treatment of advanced or recurrent endometrial cancer. (omeka.net)
Regimen6
  • Adding panitumumab to a carboplatin-containing neoadjuvant chemotherapy regimen yielded a higher rate of pathologic complete response (pCR) in patients with triple-negative inflammatory breast cancer (IBC), a small study found. (medpagetoday.com)
  • After this the investigators adopted a 3 weeks on, 1 week off approach that resulted in less intense hematological toxicity compared with the weekly regimen. (medpagetoday.com)
  • Assess the nature and degree of toxicity of this regimen in these patients. (knowcancer.com)
  • Because the addition of other drugs to this regimen has proved disappointing, Katsumata et al studied the use of a dose-dense regimen, in which paclitaxel is given on days 1, 8, and 15 and carboplatin is given on day 1. (medscape.com)
  • In addition, the combination of platinum and paclitaxel is superior to a regimen that does not include paclitaxel. (medscape.com)
  • Due to the rather high compliance rate and the moderate toxicity profile of the TCG regimen, a prospectively randomized phase III Intergroup study was initiated within the GCIG network. (bmj.com)
Hematological toxicity2
  • Further investigation of the carboplatin-based combination chemotherapy including a drug with mild hematological toxicity is warranted. (bmj.com)
  • GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes. (cdc.gov)
Cycles7
  • Participants were randomly assigned to receive carboplatin-paclitaxel (control arm) for six cycles with or without intravenous trastuzumab (experimental arm) until progression or unacceptable toxicity. (nih.gov)
  • Determine if continuation of ruxolitinib as maintenance therapy in participants who complete 6 cycles of standard chemotherapy in combination with ruxolitinib and have not experienced unacceptable toxicity or disease progression is safe and tolerable. (uchicagomedicine.org)
  • PHASE I (CYCLES 1-3): Patients receive ruxolitinib phosphate orally (PO) twice daily (BID) on days 1-21, paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15, and carboplatin IV over 30 minutes on day 1. (uchicagomedicine.org)
  • Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. (uchicagomedicine.org)
  • Toxicity-induced treatment delays occurred in 3.1% of cycles and resulted in early treatment cessation in four patients. (bmj.com)
  • Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. (ucdavis.edu)
  • Patients and methods Nineteen patients received adavosertib 175 mg twice daily (bid) for 2.5 days (five doses) in combina- tion with carboplatin (AUC 5) alone or paclitaxel (175 mg/m ) plus carboplatin, or adavosertib 225 mg bid for 2.5 days in combination with paclitaxel plus carboplatin in 21-day cycles. (sagepub.com)
Progression-Free Sur2
  • Conclusion Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival. (nih.gov)
  • The primary endpoint was an overall response rate (ORR), and secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. (elsevierpure.com)
Thrombocytopenia2
  • We conducted a pilot study to assess whether the addition of low-dose paclitaxel to carboplatin-based combination chemotherapy prevents thrombocytopenia. (bmj.com)
  • Conclusions Although low-dose paclitaxel addition did not alleviate thrombocytopenia in the setting of this pilot study, the results do not deny the existence of the "platelet-sparing effect" by low-dose paclitaxel. (bmj.com)
Intravenously2
Disease progression2
Ovarian cancer3
  • GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer. (cdc.gov)
  • It is indicated for advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy and is used in combination with carboplatin. (medscape.com)
  • To determine if the addition of bevacizumab to the second-line and maintenance phases of treatment increases the duration of overall survival relative to second-line paclitaxel and carboplatin alone in patients with recurrent platinum sensitive epithelial ovarian cancer, peritoneal primary or fallopian tube cancer. (ucsf.edu)
Chemotherapy in patients2
  • We explored efficacy and safety of adding ganitumab, a monoclonal antibody targeting IGF-1R, to carboplatin/paclitaxel (CP) chemotherapy in patients with primary EOC. (uni-muenchen.de)
  • Purpose: To evaluate the activity and toxicity of the combination of paclitaxel given by three-hour infusion, and carboplatin as first- line chemotherapy in patients with advanced breast cancer (ABC). (ucy.ac.cy)
Docetaxel and carboplatin2
  • The initial dose of Herzuma is 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 12 weeks (with paclitaxel or docetaxel) or 18 weeks (with docetaxel and carboplatin ). (rxlist.com)
  • Biocon Biologics Ltd), BT-ON013 - following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel - in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin. (who.int)
Receive paclitaxel1
Cyclophosphamide1
  • Working primarily in hospitals, outpatient care centers and physician offices, respondents reported that they collectively administered over 90 specific antineoplastic drugs in the past week, with carboplatin, cyclophosphamide and paclitaxel the most common. (cdc.gov)
Recurrent2
  • This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. (nih.gov)
  • Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. (omeka.net)
Pulmonary toxicity2
  • Administration of trastuzumab products can result in serious and fatal infusion reactions and pulmonary toxicity. (rxlist.com)
  • can result in serious and fatal infusion reactions and pulmonary toxicity. (biospace.com)
Combination11
  • Common adverse reactions when used in combination with carboplatin and paclitaxel in patients with dMMR/MSI-H endometrial cancer include rash, diarrhea, hypothyroidism, and hypertension. (drugs.com)
  • We thus designed a phase I study to define the maximum tolerated dose and dose-limiting toxicity of the combination with and without filgrastim support. (psu.edu)
  • The combination of paclitaxel and carboplatin is active in non-small cell lung cancer, and the recommended phase II doses for the combination without filgrastim support are paclitaxel 175 mg/m 2 as a 24-hour infusion with the carboplatin dose based on a target AUC of 7. (psu.edu)
  • The combination of paclitaxel, carboplatin, and bortezomib demonstrated limited clinical benefit and was associated with significant toxicity. (elsevierpure.com)
  • Standard postoperative chemotherapy is combination therapy with platinum and paclitaxel. (medscape.com)
  • However, because of a more tolerable toxicity profile, the combination of carboplatin and paclitaxel is preferred. (medscape.com)
  • The combination of paclitaxel and carboplatin is customarily given every 3 weeks (day 1 of a 21-day cycle). (medscape.com)
  • Objective This open-label Phase Ib study (NCT02341456) investigated the safety, pharmacokinetics, and clinical activity of adavosertib in combination with carboplatin alone or paclitaxel plus carboplatin in Asian patients with advanced solid tumors and defined the recommended Phase II dose. (sagepub.com)
  • Conclusions Adavosertib 175 mg bid for 2.5 days was chosen as the recommended Phase II dose in combination with pacli- taxel and carboplatin in Asian patients. (sagepub.com)
  • Adavosertib 175 mg twice daily (bid) for 2.5 days (five Patients also had to have at least one measurable lesion that doses) in combination with carboplatin (AUC 5) alone or could be accurately assessed at baseline by computed tomog- paclitaxel (175 mg/m ) plus carboplatin was considered raphy or magnetic resonance imaging and Response Evalua- tolerable in Asian patients with advanced solid tumors. (sagepub.com)
  • Figitumumab 20 mg/kg in combination with carboplatin and paclitaxel was well tolerated in chemotherapy-naïve Japanese patients with NSCLC. (omicsdi.org)
NSCLC2
Survival1
Grade2
  • No grade 3/4 nonhematological toxicity was observed. (bmj.com)
  • Grade 3/4 nonhematologic toxicities were rare and occurred in less than 10% of patients. (bmj.com)
Treatment7
  • Toxicity was not different between treatment arms, and no unexpected safety signals emerged. (nih.gov)
  • Nine patients died on study (one of which was deemed to be treatment related), and three patients ceased treatment due to toxicity or distant metastasis. (medpagetoday.com)
  • Giving ruxolitinib phosphate together with paclitaxel and carboplatin may be a better treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer compared to paclitaxel and carboplatin alone. (uchicagomedicine.org)
  • No difference in toxicity was observed in the control or treatment groups. (researchgate.net)
  • Delivery of tumoricidal doses to the primary tumor and involved lymph nodes is balanced by treatment-related toxicities, namely esophagitis, pneumonitis, and cardiac injury. (frontiersin.org)
  • Preliminary data with respect to patient characteristics, treatment compliance, and toxicity were available: 175 (10.1%) patients had FIGO stage IC-IIA and the remaining suffered from advanced disease FIGO stage IIB-IV. (bmj.com)
  • Figitumumab combined with carboplatin and paclitaxel in treatment-naive Japanese patients with advanced non-small cell lung cancer. (omicsdi.org)
Bevacizumab1
  • To identify molecular determinants that predict sensitivity or resistance to carboplatin and paclitaxel with or without bevacizumab followed with or without maintenance bevacizumab therapy. (ucsf.edu)
Trial4
  • Daily adaptive radiotherapy can improve salivary gland sparing and lead to fewer acute toxicities for patients with squamous cell head and neck cancer, according to results from a randomized trial presented at the American Society for Radiation Oncology (ASTRO) 2023 Annual Meeting. (medscape.com)
  • A randomized phase II trial is currently ongoing, testing the carboplatin-containing chemotherapy used in the study with or without the EGFR inhibitor panitumumab in patients with triple-negative IBC. (medpagetoday.com)
  • This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed by surgery. (ucdavis.edu)
  • However, the trial also showed that IP chemotherapy resulted in increased toxicity compared with IV chemotherapy. (medscape.com)
Evaluate1
  • To evaluate the frequency and severity of toxicity of carboplatin-paclitaxel with or without ramucirumab in this patient population. (ucdavis.edu)
Pharmacokinetics1
  • The aim of this study is to investigate the feasibility and determine the pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. (ucy.ac.cy)
Oncology1
  • Bristol-Myers Squibb Oncology, Princeton, NJ) and carboplatin have each shown activity against non-small cell lung cancer and they are synergistic in vitro. (psu.edu)
Doses1
  • With an initial fixed dose of paclitaxel 135 mg/m 2 given as a 24-hour infusion, carboplatin was administered in escalating doses in cohorts of three patients, based on a target area under the concentration-time curve (AUC) of 5, 7, 9, or 11 using Calvert's formula: dose (mg) = target AUC x (glomerular filtration rate + 25). (psu.edu)
Neurotoxicity1
  • P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer. (ucsf.edu)
Endometrial cancer1
  • ABTL0812 increases by 40% CT efficacy in endometrial cancer patients, and by 50% in sqNSCLC patients, without increasing CT toxicity. (abilitypharma.com)
Phase2
  • A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. (cdc.gov)
  • The phase II dose with filgrastim support will be defined as dose escalation of paclitaxel continues. (psu.edu)
Dose level1
  • no dose-limiting toxicities were observed at this dose level. (omicsdi.org)
Tolerable1